Welcome to our dedicated page for PSYENCE BIOMEDICAL SEC filings (Ticker: PBMWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PSYENCE BIOMEDICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PSYENCE BIOMEDICAL's regulatory disclosures and financial reporting.
Psyence Biomedical Ltd. has settled a shareholder dispute with KAOS Capital Ltd. and Adam Arviv. The company will pay KAOS an aggregate US $1,500,000 and release KAOS from a prior CDN $75,000 cost award ordered by the Ontario Superior Court.
As part of the settlement, KAOS will sell all its 50,220 common shares of Psyence to a third party designated by the company at US $5 per share. The deal includes a full retraction of KAOS’s unproven allegations, mutual releases of claims, and no admission of liability or wrongdoing by Psyence, its board, or officers. The settlement will be funded from cash on hand.
Psyence Biomedical Ltd. has settled a shareholder dispute with KAOS Capital Ltd. and Adam Arviv. The company will pay KAOS an aggregate US $1,500,000 and release KAOS from a prior CDN $75,000 cost award ordered by the Ontario Superior Court.
As part of the settlement, KAOS will sell all its 50,220 common shares of Psyence to a third party designated by the company at US $5 per share. The deal includes a full retraction of KAOS’s unproven allegations, mutual releases of claims, and no admission of liability or wrongdoing by Psyence, its board, or officers. The settlement will be funded from cash on hand.
Psyence Biomedical Ltd. is consolidating its common shares through a 1-for-6.25 reverse stock split. The company now expects its shares to begin trading on a post-consolidated basis at the opening of the market on February 2, 2026.
At the effective time, every 6.25 issued and outstanding common shares will be combined into one share, and the number of shares underlying outstanding warrants and other equity instruments and their exercise prices will be adjusted proportionately under their terms. As of January 21, 2026, Psyence BioMed had 6,388,604 common shares issued and outstanding; following the consolidation it will have 1,022,177 common shares issued and outstanding.
The reverse split is intended, among other things, to support the company’s ability to maintain compliance with Nasdaq continued listing standards. The consolidation applies uniformly to all shareholders, with only minor differences from rounding of fractional shares. Continental Stock Transfer & Trust Company will act as exchange and transfer agent, and most shareholders will not need to take action.
Psyence Biomedical Ltd. filed a report explaining that its annual and special shareholder meeting, originally set for January 22, 2026, was adjourned because not enough shares were represented to reach quorum. The meeting has been rescheduled to February 12, 2026 at 9:00 a.m. New York time / 4:00 p.m. Cape Town time in Cape Town, South Africa, and the record date for voting remains December 23, 2025. The company is working with its proxy agents to obtain sufficient shareholder participation and notes that there is no assurance quorum will be reached, highlighting potential delays or challenges around completing the planned meeting business.
Psyence Biomedical Ltd. filed a report explaining that its annual and special shareholder meeting, originally set for January 22, 2026, was adjourned because not enough shares were represented to reach quorum. The meeting has been rescheduled to February 12, 2026 at 9:00 a.m. New York time / 4:00 p.m. Cape Town time in Cape Town, South Africa, and the record date for voting remains December 23, 2025. The company is working with its proxy agents to obtain sufficient shareholder participation and notes that there is no assurance quorum will be reached, highlighting potential delays or challenges around completing the planned meeting business.